Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis
about
Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review.Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania.Artemisinin resistance--modelling the potential human and economic costs.Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99-411, with long acting prescription antimalarials, lumefantrine and piperaquine.An Economic Evaluation of the Posttreatment Prophylactic Effect of Dihydroartemisinin-Piperaquine Versus Artemether-Lumefantrine for First-Line Treatment of Plasmodium falciparum Malaria Across Different Transmission Settings in AfricaBudget Impact Analysis of Using Dihydroartemisinin-Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania.Assessment of Burden of Malaria in Gwanda District, Zimbabwe, Using the Disability Adjusted Life Years.Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in AfricaCost-effectiveness of artemisinin-naphthoquine versus artemether-lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children.
P2860
Q33862627-9663CEFB-74FD-4EF3-861B-8F057593FE64Q34227179-A8EE4D63-FCF0-4EC3-A4AF-43DD38C46226Q34623414-BA477F7F-25B3-4200-A350-E38EC4345BFDQ34677891-BD7FC862-2BDD-4503-BADB-20B6B33CF912Q36316695-B97E747D-ECDC-4933-80B7-2C673EB7634AQ36436334-C161B981-01D5-4ABB-AEFF-B8AFCDC191E2Q36615103-11511D66-9CC4-49FC-9D89-DBC27A74A63FQ36634018-F12CDEDB-E2DA-437B-B025-A0BD880CAC57Q43923958-7B8BDFEC-73F7-4EE3-BCC3-87450E0B0FCEQ47143596-4DAC1E80-5253-4781-9E91-91DC382C52D4
P2860
Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@ast
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@en
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@nl
type
label
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@ast
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@en
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@nl
prefLabel
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@ast
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@en
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@nl
P2860
P1433
P1476
Dihydroartemisinin-piperaquine ...... a cost-effectiveness analysis
@en
P2093
Johannes Pfeil
Yeşim Tozan
P2860
P304
P356
10.1371/JOURNAL.PONE.0095681
P407
P577
2014-01-01T00:00:00Z